Citadel Advisors’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$197M Sell
3,253,900
-694,300
-18% -$40.5M 0.03% 456
2025
Q4
$213M Buy
3,948,200
+43,800
+1% +$2.11M 0.03% 459
2025
Q3
$176M Buy
3,904,400
+374,900
+11% +$17.5M 0.03% 537
2025
Q2
$163M Sell
3,529,500
-1,202,900
-25% -$59M 0.03% 490
2025
Q1
$289M Sell
4,732,400
-95,000
-2% -$5.54M 0.05% 260
2024
Q4
$273M Sell
4,827,400
-2,312,500
-32% -$129M 0.05% 289
2024
Q3
$369M Buy
7,139,900
+1,420,100
+25% +$66.6M 0.07% 196
2024
Q2
$238M Buy
5,719,800
+1,821,500
+47% +$81.5M 0.05% 290
2024
Q1
$211M Buy
3,898,300
+1,083,400
+38% +$55.2M 0.04% 353
2023
Q4
$144M Buy
2,814,900
+401,600
+17% +$21.1M 0.03% 493
2023
Q3
$140M Buy
2,413,300
+909,700
+61% +$55.7M 0.03% 466
2023
Q2
$96.2M Sell
1,503,600
-226,800
-13% -$15.2M 0.02% 633
2023
Q1
$120M Sell
1,730,400
-1,835,900
-51% -$129M 0.03% 540
2022
Q4
$257M Buy
3,566,300
+560,000
+19% +$42.2M 0.06% 252
2022
Q3
$214M Sell
3,006,300
-955,700
-24% -$69.3M 0.05% 287
2022
Q2
$305M Sell
3,962,000
-72,200
-2% -$5.5M 0.08% 168
2022
Q1
$295M Buy
4,034,200
+2,772,100
+220% +$186M 0.06% 219
2021
Q4
$78.7M Sell
1,262,100
-543,800
-30% -$31.9M 0.02% 828
2021
Q3
$107M Buy
1,805,900
+931,300
+106% +$61.3M 0.02% 621
2021
Q2
$58.4M Sell
874,600
-73,800
-8% -$4.81M 0.01% 1009
2021
Q1
$59.9M Sell
948,400
-624,300
-40% -$38.8M 0.01% 904
2020
Q4
$97.6M Sell
1,572,700
-1,105,400
-41% -$68M 0.03% 571
2020
Q3
$161M Buy
2,678,100
+1,038,100
+63% +$62.5M 0.05% 262
2020
Q2
$96.4M Sell
1,640,000
-29,900
-2% -$1.79M 0.03% 424
2020
Q1
$93.1M Buy
1,669,900
+96,600
+6% +$5.9M 0.04% 360
2019
Q4
$101M Buy
1,573,300
+650,300
+70% +$37.2M 0.04% 385
2019
Q3
$46.8M Sell
923,000
-86,400
-9% -$4.06M 0.02% 795
2019
Q2
$45.8M Sell
1,009,400
-905,800
-47% -$42.2M 0.02% 779
2019
Q1
$91.4M Sell
1,915,200
-732,300
-28% -$36.5M 0.05% 398
2018
Q4
$138M Sell
2,647,500
-254,100
-9% -$13.7M 0.08% 222
2018
Q3
$180M Sell
2,901,600
-543,500
-16% -$32.3M 0.08% 201
2018
Q2
$191M Buy
3,445,100
+875,200
+34% +$47.3M 0.09% 164
2018
Q1
$163M Sell
2,569,900
-760,200
-23% -$48.9M 0.09% 171
2017
Q4
$204M Buy
3,330,100
+745,900
+29% +$46.7M 0.12% 134
2017
Q3
$165M Buy
2,584,200
+578,200
+29% +$33.8M 0.13% 121
2017
Q2
$112M Buy
2,006,000
+879,100
+78% +$47.8M 0.09% 196
2017
Q1
$61.3M Sell
1,126,900
-36,800
-3% -$2.02M 0.06% 355
2016
Q4
$68M Sell
1,163,700
-1,057,000
-48% -$57.8M 0.07% 276
2016
Q3
$120M Buy
2,220,700
+1,951,400
+725% +$125M 0.12% 122
2016
Q2
$19.8M Sell
269,300
-150,700
-36% -$10.6M 0.02% 789
2016
Q1
$26.8M Buy
420,000
+257,600
+159% +$16.2M 0.03% 580
2015
Q4
$11.2M Sell
162,400
-68,100
-30% -$4.5M 0.01% 1187
2015
Q3
$13.6M Buy
230,500
+20,800
+10% +$1.32M 0.01% 1136
2015
Q2
$14M Buy
209,700
+11,200
+6% +$738K 0.01% 1248
2015
Q1
$12.8M Sell
198,500
-82,500
-29% -$5.16M 0.01% 1259
2014
Q4
$16.6M Buy
281,000
+34,100
+14% +$1.92M 0.02% 1068
2014
Q3
$12.6M Sell
246,900
-105,600
-30% -$5.27M 0.01% 1209
2014
Q2
$17.1M Buy
352,500
+71,300
+25% +$3.51M 0.02% 906
2014
Q1
$14.6M Sell
281,200
-267,200
-49% -$14.2M 0.02% 1037
2013
Q4
$29.1M Sell
548,400
-46,900
-8% -$2.39M 0.04% 605
2013
Q3
$27.6M Buy
595,300
+74,100
+14% +$3.25M 0.04% 571
2013
Q2
$23.3M Buy
+521,200
New +$22.6M 0.04% 580

Other funds holding BMY

Citadel Advisors's BMY Position: Q1 2026 in Review

Citadel Advisors increased its Bristol-Myers Squibb (BMY) stake by 46% in Q1 2026, buying an estimated $27.5M and bringing the position to 1,494,234 shares worth $90.6M. The position accounts for 0.01% of the portfolio, ranked #884.

Citadel Advisors first reported a position in BMY in Q2 2013 and has held it in 52 quarters since. The position peaked at $456M in Q2 2024. 2,518 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Citadel Advisors held 1,494,234 shares of Bristol-Myers Squibb worth $90.6M as of Q1 2026.
  • Citadel Advisors bought 471,773 Bristol-Myers Squibb shares in Q1 2026, an estimated $27.5M.
  • Bristol-Myers Squibb made up 0.01% of Citadel Advisors's portfolio in Q1 2026, its #884 holding.
  • Citadel Advisors first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 52 quarters since.
  • Citadel Advisors's Bristol-Myers Squibb position peaked at $456M in Q2 2024.
  • 2,518 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.